Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Although semaglutide is currently the only GLP-1 RA with a specific indication for CKD progression, other agents in the class such as liraglutide and dulaglutide remain clinically relevant in the management of T2D and may offer renal benefits
*Average weight-loss figures reflect randomized trials of the FDA-approved branded molecules (SURMOUNT for tirzepatide, STEP for semaglutide), not compounded products, and individual results vary
Current management generally begins with lifestyle measures, metformin, and insulin when needed, while additional agents have gradually entered the pediatric landscape
The tablet was administered with 240 mL of water
When injected in quantities higher than prescribed, these receptor pathways become overstimulated, amplifying both therapeutic and adverse effects
US$ 23.37
US$ 27.27
US$ 26.12
US$ 27.34
